Revenue
No reported data
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $2.1M | $534,000 | $332,000 | $347,000 |
| Operating income | −$6.2M | −$1.3M | −$635,000 | −$895,000 |
| EBITDAderived | −$5.6M | — | — | — |
| Net income | −$3.3M | −$1.5M | −$600,000 | −$779,000 |
| Basic EPSper diluted share | $4.90 | $805.20 | $494.40 | $0.60 |
| Diluted EPSper diluted share | $4.90 | $805.20 | $494.40 | $0.60 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | Izraeli TomerChief Executive Officer | SellOrdinary Shares | 500 | $11.85 | $5.9K | 31.5K |
| Mar 31, 2026Form 4 | Carmel LironDirector | SellOrdinary Shares | 942 | $12.36 | $11.6K | 3.1K |
| Mar 31, 2026Form 4 | Adler OzDirector | SellOrdinary Shares | 3.3K | $12.05 | $39.7K | 19.9K |
| Mar 30, 2026Form 4 | Carmel LironDirector | SellOrdinary Shares | 100 | $11.00 | $1.1K | 4.1K |
| Mar 30, 2026Form 4 | Izraeli TomerChief Executive Officer | SellOrdinary Shares | 3.9K | $10.90 | $42.5K | 32.0K |